TheraSphere™ Y-90 Therapy: Impact on PFS, TTP, and Overall Survival
Prof. Boris Guiu, MD, PhD, Interventional Radiologist, examines how TheraSphere™ Y-90 Therapy is reshaping multimodal treatment strategies for primary liver cancer. Drawing on clinical evidence and real-world experience, he highlights the therapy’s role in extending progression-free survival (PFS), delaying time to progression (TTP) and improving overall survival (OS).
His insights emphasise how integrating TheraSphere™ Y-90 Therapy into multidisciplinary care pathways can directly influence outcomes and expand options for patients with hepatocellular carcinoma (HCC).
Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.